ENTA – Enanta Pharmaceuticals Inc
Float Short %
13.75
Margin Of Safety %
Put/Call OI Ratio
0.03
EPS Next Q Diff
-0.26
EPS Last/This Y
1.47
EPS This/Next Y
0.72
Price
8.82
Target Price
17.2
Analyst Recom
2
Performance Q
53.57
Relative Volume
0.7
Beta
0.83
Ticker: ENTA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | ENTA | 7.41 | 0.12 | 0.10 | 737 |
| 2025-07-28 | ENTA | 8.01 | 0.12 | 0.00 | 759 |
| 2025-07-29 | ENTA | 8.08 | 0.11 | 0.00 | 783 |
| 2025-07-30 | ENTA | 7.6 | 0.09 | 999.99 | 941 |
| 2025-07-31 | ENTA | 7.57 | 0.15 | 999.99 | 1011 |
| 2025-08-01 | ENTA | 7.11 | 0.15 | 0.05 | 1013 |
| 2025-08-04 | ENTA | 7.09 | 0.14 | 999.99 | 1073 |
| 2025-08-05 | ENTA | 7.39 | 0.14 | 0.00 | 1073 |
| 2025-08-06 | ENTA | 7.12 | 0.14 | 0.00 | 1073 |
| 2025-08-07 | ENTA | 6.99 | 0.13 | 0.00 | 1148 |
| 2025-08-08 | ENTA | 6.9 | 0.13 | 0.00 | 1149 |
| 2025-08-11 | ENTA | 6.49 | 0.13 | 0.00 | 1160 |
| 2025-08-12 | ENTA | 6.85 | 0.08 | 0.00 | 1778 |
| 2025-08-13 | ENTA | 7.59 | 0.05 | 0.08 | 2591 |
| 2025-08-14 | ENTA | 7.74 | 0.05 | 0.00 | 2596 |
| 2025-08-15 | ENTA | 8.01 | 0.05 | 0.00 | 2623 |
| 2025-08-18 | ENTA | 8.19 | 0.03 | 0.00 | 2440 |
| 2025-08-19 | ENTA | 8.44 | 0.03 | 0.00 | 2456 |
| 2025-08-20 | ENTA | 8.78 | 0.03 | 0.00 | 2454 |
| 2025-08-21 | ENTA | 8.59 | 0.03 | 0.00 | 2457 |
| 2025-08-22 | ENTA | 8.82 | 0.03 | 0.00 | 2457 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | ENTA | 7.40 | 24.3 | - | -3.89 |
| 2025-07-28 | ENTA | 8.00 | 24.3 | - | -3.89 |
| 2025-07-29 | ENTA | 8.10 | 24.3 | - | -3.89 |
| 2025-07-30 | ENTA | 7.61 | 24.3 | - | -3.89 |
| 2025-07-31 | ENTA | 7.58 | 24.3 | - | -3.89 |
| 2025-08-01 | ENTA | 7.11 | 17.3 | - | -4.22 |
| 2025-08-04 | ENTA | 7.10 | 17.3 | - | -4.22 |
| 2025-08-05 | ENTA | 7.41 | 17.3 | - | -4.22 |
| 2025-08-06 | ENTA | 7.17 | 17.3 | - | -4.22 |
| 2025-08-07 | ENTA | 6.99 | 17.3 | - | -4.22 |
| 2025-08-08 | ENTA | 6.90 | 17.3 | - | -4.22 |
| 2025-08-11 | ENTA | 6.50 | 17.3 | - | -4.22 |
| 2025-08-12 | ENTA | 6.84 | 17.3 | - | -4.22 |
| 2025-08-13 | ENTA | 7.58 | 17.3 | - | -4.22 |
| 2025-08-14 | ENTA | 7.70 | 17.3 | - | -4.22 |
| 2025-08-15 | ENTA | 8.01 | 17.3 | - | -4.01 |
| 2025-08-18 | ENTA | 8.19 | 34.9 | - | -4.01 |
| 2025-08-19 | ENTA | 8.39 | 34.9 | - | -4.01 |
| 2025-08-20 | ENTA | 8.78 | 34.9 | - | -4.01 |
| 2025-08-21 | ENTA | 8.55 | 34.9 | - | -4.01 |
| 2025-08-22 | ENTA | 8.82 | 23.0 | - | -4.01 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | ENTA | 3.06 | -8.11 | 12.40 |
| 2025-07-28 | ENTA | 3.06 | -8.76 | 12.40 |
| 2025-07-29 | ENTA | 3.06 | -8.76 | 12.40 |
| 2025-07-30 | ENTA | 3.06 | -8.76 | 12.40 |
| 2025-07-31 | ENTA | 3.06 | -8.76 | 12.40 |
| 2025-08-01 | ENTA | 3.06 | -8.76 | 12.40 |
| 2025-08-04 | ENTA | 3.06 | -8.81 | 12.40 |
| 2025-08-05 | ENTA | 3.06 | -8.81 | 12.40 |
| 2025-08-06 | ENTA | 3.06 | -8.81 | 12.40 |
| 2025-08-07 | ENTA | 3.06 | -8.81 | 12.40 |
| 2025-08-08 | ENTA | 3.06 | -8.81 | 12.40 |
| 2025-08-11 | ENTA | 3.06 | -8.75 | 12.40 |
| 2025-08-12 | ENTA | 3.06 | -8.75 | 13.75 |
| 2025-08-13 | ENTA | 0.00 | -8.75 | 13.75 |
| 2025-08-14 | ENTA | 0.00 | -8.75 | 13.75 |
| 2025-08-15 | ENTA | 0.00 | -8.75 | 13.75 |
| 2025-08-18 | ENTA | 0.00 | -11.41 | 13.75 |
| 2025-08-19 | ENTA | 0.00 | -11.41 | 13.75 |
| 2025-08-20 | ENTA | 0.00 | -11.41 | 13.75 |
| 2025-08-21 | ENTA | 0.00 | -11.41 | 13.75 |
| 2025-08-22 | ENTA | 0.00 | -11.41 | 13.75 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.85
Avg. EPS Est. Current Quarter
-1.05
Avg. EPS Est. Next Quarter
-1.11
Insider Transactions
Institutional Transactions
-11.41
Beta
0.83
Average Sales Estimate Current Quarter
15
Average Sales Estimate Next Quarter
16
Fair Value
Quality Score
20
Growth Score
25
Sentiment Score
51
Actual DrawDown %
91.4
Max Drawdown 5-Year %
-95.6
Target Price
17.2
P/E
Forward P/E
PEG
P/S
2.91
P/B
2.38
P/Free Cash Flow
EPS
-4.32
Average EPS Est. Cur. Y
-4.01
EPS Next Y. (Est.)
-3.3
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-141.98
Relative Volume
0.7
Return on Equity vs Sector %
-140.8
Return on Equity vs Industry %
-127.8
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.09
EBIT Estimation
Enanta Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 131
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today
news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance
stock history ENTA – Enanta Pharmaceuticals Inc invest stock market
stock prices ENTA premarket after hours
ticker ENTA fair value insiders trading